Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salophen-10-propionate iron chelate is a synthetic small molecule classified as a chelating agent, specifically designed to bind iron ions. Its structure is based on the salophen ligand (a Schiff base derived from salicylaldehyde and o-phenylenediamine) modified with a propionate group, complexed with an iron ion. As an experimental compound, it has not been approved for clinical use in any country and has no known marketed indications or completed clinical trials. Chelating agents like this are generally investigated for their ability to tightly bind metal ions such as iron, potentially modulating their biological activity or facilitating their removal from the body[2][3]. The specific mechanism of action for this compound would involve sequestration of free or loosely bound iron through strong coordination bonds, thereby reducing its availability for participation in redox reactions or other biological processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salophen-10-propionate iron chelate.